灵芝S3发酵培养基的优化及其对镰刀菌的抑制

以发酵液对镰刀菌孢子萌发的抑制率为指标,通过单因素试验,研究不同碳源、氮源、生长因子对灵芝S3发酵液抑菌活性的影响。运用响应面法,对各营养组分的含量进行优化。优化后碳源、氮源、生长因子含量分别为：乳糖3.04%,蛋白胨0.28%,VB1 0.0047%,抑菌率为91.71%,比基础发酵培养基增加了42.15%。发酵液作用12h后,光学显微镜下镰刀菌菌丝出现膨大和消融等畸变,并出现典型的“念珠状”形态;透射电镜显示镰刀菌孢子内出现大量空泡、原生质收缩,说明灵芝S3发酵液中的活性物质可有效抑制菌丝生长及孢子萌发。     

灵芝多糖对荷瘤小鼠肿瘤免疫系统的影响

目的:观察灵芝多糖对荷瘤小鼠免疫系统的影响.方法:纯系BALB/c小鼠30只,用U14瘤细胞荷瘤建立动物模型,随机平均分为三组:灵芝多糖治疗组、环磷酰胺治疗组、生理盐水对照组.观察灵芝多糖对荷瘤小鼠NK细胞活性、淋巴细胞转化率、TNF-α等免疫指标的影响.结果:灵芝多糖能够显著提高治疗组小鼠的NK细胞活性、淋巴细胞转化率和血清中TNF-α、IL-2的含量.结论:灵芝多糖能够显著提荷瘤小鼠免疫系统的活性.     

灵芝液体发酵条件的研究

本文研究了某些因素对灵芝液体发酵的影响。4天菌龄的液体菌种发酵效果最好;300毫升三角瓶以装入60毫升培养液发酵较合适;蔗糖、花生饼粉分别为灵芝液体发酵的理想碳、氮源;液体发酵培养基最佳配方为:蔗糖4％、花生饼粉3％、硫酸铵0.15％、磷酸二氢钾0.15％,可得灵芝菌丝体百分干重为0.83,每100毫升发酵液得粗多糖0.3克。     

中药提取液对灵芝深层发酵的影响

我国中医药历史悠久 ,中药资源丰富 ,为保证广大人们的身体健康起到巨大作用。但近几十年来 ,我国在中药现代化方面进展缓慢 ,其中原因之一就是中药加工技术陈旧[1] ,近来有学者提出了中药发酵制药技术[1,2 ] 。药用真菌是中药的组成部分 ,它们中的许多种类都能以液体发酵进行生产[3] ,以适当的中药为培养基或在培养基中添加适量的中药 ,利用它们强大的分解转化能力 ,不仅可对中药中的纤维、糖类和蛋白等物质加以利用 ,而且在代谢过程中可能对中药中的一些成分进行转化 ,从而提高中药活性成分在复合制剂中的比例及效价 ;另外中药中的某些成…     

蜜环菌多糖对小鼠腹腔巨噬细胞免疫功能的影响

从蜜环菌菌索提取的多糖（ＭＨＧ）能在体外显著增强小鼠腹腔巨噬细胞吞噬中性红的作用,并可诱生巨噬细胞产生一氧化氮。在高浓度时,对巨噬细胞分泌ＩＬ－１有一定的作用。     

蛋白质粉对小鼠免疫功能的影响

目的探讨蛋白质粉对正常小鼠免疫调节作用。方法将BALB/c小鼠随机分为3批,每批分为4组,分别进行了小鼠免疫器官/体质量比值测定和小鼠碳廓清实验;绵羊红细胞诱导小鼠DTH、抗体生成细胞检测和血清凝血素测定（HC50）;ConA诱导的小鼠脾淋巴细胞转化实验和乳酸锂脱氢酶法（LDH）测定NK细胞活性;小鼠腹腔巨噬细胞吞噬鸡红细胞实验。结果10.00 g/kg剂量的蛋白质粉可增强绵羊红细胞诱导小鼠DTH能力（P〈0.05）,促进抗体生成细胞数的生成（P〈0.01）。3.33 g/kg和10.00 g/kg剂量组能促进ConA诱导的小鼠脾淋巴细胞转化能力（P〈0.05或P〈0.01）和血清凝血素的生成（P〈0.05）;三个剂量组均能提高小鼠腹腔巨噬细胞吞噬鸡红细胞能力（P〈0.05或P〈0.01）;3.33 g/kg和10.00 g/kg剂量组能提高NK细胞活性（P〈0.05）;但对小鼠碳廓清能力和免疫器官/体重比值无明显影响。结论蛋白质粉对正常小鼠的细胞、体液免疫和单核-巨噬细胞功能和NK功能有促进作用,即具有增强免疫力功能。     

肺炎克雷伯菌生物膜对小鼠巨噬细胞免疫功能的影响

目的研究肺炎克雷伯菌生物膜(BF)对小鼠腹腔巨噬细胞TLRs mRNA和细胞因子表达的影响,探索机体抗BF感染免疫的特点。方法将雄性昆明种小鼠40只随机分成2组,一组腹腔植入体外形成肺炎克雷伯菌BF的硅胶片,建立留置性医疗装置BF感染模型实验组,另一组植入与实验组同等量的浮游菌作为对照组。实时定量PCR分析2组巨噬细胞TLRs mRNA的表达水平,双抗体夹心ELISA法测定细胞因子的含量。结果实验BF组巨噬细胞TLR2、TLR4 mRNA表达量是对照浮游菌组的0.23和0.24倍;而TLR5、TLR9两组表达差异无显著性。实验BF组刺激前后IL-1、IL-2的差值明显低于对照浮游菌组,而IL-4则相反(P0.01)。结论与浮游菌相比,BF能下调小鼠腹腔巨噬细胞TLR2、TLR4的表达,机体的免疫应答朝着Th2型免疫反应发展,这可能是BF相对浮游菌更容易逃脱机体免疫防御系统、引起慢性感染的机制之一。     

参芝发酵产物的抗肿瘤活性及其对小鼠免疫功能的影响

为了探索红参水煎液的灵芝发酵产物对H22荷瘤小鼠的抗肿瘤活性及其对小鼠免疫功能的影响,通过体内抗肿瘤实验和增强免疫功能实验从抑瘤率、对免疫器官的影响指数、对非特异性免疫、体液免疫及细胞免疫的影响5个方面对该产物做了功能性评价。结果表明,在抗肿瘤实验中,参芝发酵产物高剂量组的抑瘤率达到51.65%,脾指数和胸腺指数均高于对照组和环磷酰胺(CTX)组;增强免疫功能实验中,3个实验的给药组小鼠和对照组小鼠相比都有显著性差异(P<0.01)。由此可见,将灵芝与人参在发酵层次上配伍具有显著的抑制荷瘤小鼠肿瘤生长及增强小鼠免疫功能的作用。     

灵芝多糖GLP 抑制小鼠骨肉瘤细胞S-180 在体内生长的作用机制

目的:探讨灵芝多糖成分(GLP)抑制肿瘤的作用机制。方法:在小鼠右腋皮下接种1×106TC-1细胞后7天后,用100mg/kg、200mg/kg和400mg/kg 3种剂量给小鼠口服灌胃给药20天,然后观察肿瘤的重量,并用ELISA检测小鼠血清中IL-2、IL-6和TNF-alpha,用流式细胞仪检测其外周血中CD4+和CD8+。结果:100mg/kg、200mg/kg和400mg/kg 3种剂量给小鼠口服灌胃给药20天,与对照组比较,抑瘤率分别可以达到53%、59%和58%,P<0.05;小鼠外周血血清中的IL-2从1.27ng/mL提高到了2.88ng/mL,P<0.05;TNF-α从1.05ng/mL提高到了1.82ng/mL,P<0.05;而IL-6则没有明显的变化。CD4+细胞水平升高(从54.80%提高到了58.27%),但差异无统计学意义(P>0.05);CD8+细胞明显增多(从24.15%提高到了45.36%),差异有统计学意义(P<0.05)。结论:GLP有明显抑瘤作用,但抑瘤作用与GLP剂量不存在依赖关系。GLP对肿瘤细胞生长的抑制是通过提高小鼠的细胞免疫能力来实现,而并非直接杀伤肿瘤细胞。     

A short-term dietary supplementation with high doses of vitamin E increases NK cell cytolytic activity in advanced colorectal cancer patients

Cancer patients with advanced disease display signs of immune suppression, which constitute a major obstacle for effective immunotherapy. Both T cells and NK cells are affected by a multitude of mechanisms of which the generation of reactive oxygen species is of major importance. Therefore, we hypothesized that two weeks of high-dose treatment with the anti-oxidant vitamin E may enhance NK cell function in cancer patients by protecting from oxidative stress. Seven patients with colorectal cancer (Dukes stage C and D) received a daily dose of 750 mg of vitamin E during a period of two weeks and the function, phenotype and receptor expression of NK cells were analyzed. The short-term vitamin E treatment significantly improved NK cell cytolytic activity in six out of the seven patients analyzed. The increased NK cell activity in patients’ PBMC was not due to increased numbers of NK cells or an increase in the proportion of the CD56^dim NK cell subpopulation. Furthermore, neither an increased perforin expression nor an enhanced ability of NK cells to produce IFN-γ was observed as a result of vitamin E treatment. Finally, vitamin E treatment was associated with a minor, but consistent, induction of NKG2D expression in all patients analyzed. In conclusion, this pilot study demonstrates that vitamin E may boost NK cell function in patients with colorectal cancer. Further studies are warranted to explore the potential of vitamin E as an adjuvant for immunotherapy against cancer and to determine the underlying mechanism(s) behind vitamin E induced NK cell activation.     

Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor

Human monocytes exposed in vitro to recombinant macrophage-colony-stimulating factor (rhMCSF) differentiate into monocyte-derived macrophages (MDM), which mediate efficient antibodydependent cytotoxicity (ADCC) against tumor cells. We and others have shown that this form of ADCC is unusual in that phagocytosis, rather than extracellular lysis, appears to play the major role in target cell killing. In this study, we asked whether the phagocytic form of cytotoxicity seen with ADCC could occur in the absence of an opsonizing antibody. We now report that, whereas cell lines derived from solid tumors are often resistant to antibody-independent cytotoxicity, malignant cells of lymphoid origin appear particularly susceptible to such antibody-independent killing. We found that all of nine lymphocytic leukemia and lymphoma cell lines tested in a total of 35 experiments, plus all four samples of fresh leukemic blasts, were consistently susceptible to antibody-independent MDM cytotoxicity. Antibody-independent cytotoxicity against these cells was efficient (40%–63% killing) at effector: target (E:T) ratios as low as 2:1. Like ADCC, antibody-independent cytotoxicity involved phagocytosis of target cells, as demonstrated by ingestion of fluorescently labeled targets and analysis by flow cytometry. At the time of phagocytosis, the majority of target cells retained membrane integrity, as indicated by the direct transfer of intracellular [⁵¹Cr]chromate from radiolabeled targets to phagocytosing MDM, without release of the label into the medium. However, in contrast to ADCC, we found that the degree of antibody-independent cytotoxicity was not a function of the E:T ratio. Instead, a constant proportion of the available target cells were killed regardless of the E:T ratio, suggesting that target cell recognition, rather than effector cell potency, might be the limiting factor in determining cytotoxicity. In additional experiments, we have also identified a second tumor cell type, nueroblastoma, as being susceptible to antibody-independent phagocytosis (all of five cell lines tested, cytotoxicity 40%–93%, E:T=3:1). Our data thus indicate that the cytotoxicity induced by rhMCSF is not confined to antibody-mediated killing, and that phagocytosis can play a significant role in target cell destruction even in the absence of opsonizing antibody.Supported in part by grants CA-33049 and CA-53624 from the National Institutes of Health, grant IRG-174b from the American Cancer Society, the Friends of Children Toys-R-Us Foundation. Inc., and the Robert Steel Foundation     

Association of immune parameters with clinical outcome in stage III colon cancer: results of Southwest Oncology Group Protocol 9009

Levamisole (LMS), utilized in the adjuvant treatment of patients with stage III colon cancer, is immunomodulatory. To determine whether alterations in immune parameters before, during and after 12 months of 5FU/LMS therapy correlate with disease-free survival, 38 patients enrolled on Southwest Oncology Group (SWOG) protocol 8899 received extensive lymphocyte phenotypic analysis prior to therapy and 3, 6, 12 and 15 months after treatment initiation. The median follow-up of patients is 41 months. Significant increases in the proportion and total number of CD56⁺ natural killer cells were seen, starting at 3 months and continuing until 15 months (P < 0.001). Increases in the total numbers of cells expressing CD25 (interleukin-2 receptor), VLA4 and the combinations of CD4: CD45RA and CD4:CDw29 were not evident during therapy but were seen at 15 months (P < 0.05: CD25, CD4:CDw29, CD4:CD45RA; P < 0.001: VLA4). Low levels of CD8⁺ cells prior to treatment initiation and after 3 months of therapy correlated with early relapse within the first year of 5FU/LMS treatment. Patients who have remained disease-free (n = 22, median follow-up 45 months) demonstrated increases in the total numbers of CD8⁺, CD25⁺, CD56⁺, VLA4⁺, CD4: CDw29 and CD4:CD45RA cells, primarily at 15 months. In contrast, patients who relapsed had decreased numbers of CD8⁺, CD4:CDw29, CD4: CD45RA and VLA4⁺ cells and minimal increases in CD56⁺ and CD25⁺ cells. Statistically significant differences between the late-relapse group and the group remaining disease-free were seen for CD25⁺, CD4: CD45RA and CD4:CDw29 cells at the 15-month assay time (P = 0.0276, P = 0.0349, P = 0.0178 respectively). In conclusion, multiple alterations in lymphocyte phenotype, with increases in the proportion and total number of cells involved in cell-mediated immune responses, were seen during and especially following completion of therapy with 5FU/LMS. Many of these changes are significantly associated with clinical outcome and may be useful for risk stratification of stage III colon cancer patients following completion of adjuvant therapy. Received: 9 July 1999 / Accepted: 11 August 1999     

Tumor-associated macrophages: Effectors of angiogenesis and tumor progression

Tumor-associated macrophages (TAMs) are a prominent inflammatory cell population in many tumor types residing in both perivascular and avascular, hypoxic regions of these tissues. Analysis of TAMs in human tumor biopsies has shown that they express a variety of tumor-promoting factors and evidence from transgenic murine tumor models has provided unequivocal evidence for the importance of these cells in driving angiogenesis, lymphangiogenesis, immunosuppression, and metastasis. This review will summarize the mechanisms by which monocytes are recruited into tumors, their myriad, tumor-promoting functions within tumors, and the influence of the tumor microenvironment in driving these activities. We also discuss recent attempts to both target/destroy TAMs and exploit them as delivery vehicles for anti-cancer gene therapy.     

灵芝多糖抗肿瘤作用的初步探讨

目的 :初步探讨灵芝多糖对小鼠肿瘤的抑制作用。方法 :观察灵芝多糖对 S180 、U14腹水型荷瘤小鼠生存期的影响 ,了解灵芝多糖对 S180 、U14、H2 2 肿瘤细胞有无直接杀伤作用 ,以寻找治疗肿瘤的新方法。结果 :灵芝多糖能够显著延长荷瘤小鼠的生存期 (P<0 .0 5) ,治疗组小鼠的生存期比对照组小鼠的生存期明显延长 ,但是灵芝多糖对肿瘤细胞无直接杀伤作用 (P<0 .0 5)。结论 :灵芝多糖抗肿瘤作用是通过机体的免疫系统介导的。     

微生物发酵四君子汤制剂对荷瘤小鼠抗氧化功能的影响

目的探讨微生物发酵四君子汤制剂(FSJZD)对荷瘤小鼠抗氧化能力的影响。方法通过建立小鼠S180肿瘤模型,分别采用黄嘌呤法、硫代巴比妥酸法、硝酸还原酶法检测血清中的超氧化物歧化酶(SOD)、丙二醛(MDA)和一氧化氮(NO)含量,研究FSJZD的抗氧化能力。结果 FSJZD可显著升高荷瘤小鼠及CTX治疗荷瘤小鼠所致免疫抑制模型血清中的SOD水平,明显降低CTX所致免疫抑制小鼠血清中NO和MDA含量。结论 FSJZD能够显著提高荷瘤机体的抗氧化能力、降低化疗对机体产生的危害作用。